Form 8-K - Current report:
SEC Accession No. 0001213900-23-019225
Filing Date
2023-03-10
Accepted
2023-03-10 16:48:56
Documents
13
Period of Report
2023-03-10
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea175045-8k_pasithea.htm   iXBRL 8-K 26560
  Complete submission text file 0001213900-23-019225.txt   245414

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE ktta-20230310.xsd EX-101.SCH 4015
3 XBRL DEFINITION FILE ktta-20230310_def.xml EX-101.DEF 26681
4 XBRL LABEL FILE ktta-20230310_lab.xml EX-101.LAB 36819
5 XBRL PRESENTATION FILE ktta-20230310_pre.xml EX-101.PRE 25305
7 EXTRACTED XBRL INSTANCE DOCUMENT ea175045-8k_pasithea_htm.xml XML 5697
Mailing Address 2110 NARCISSUS CT VENICE CA 90291
Business Address 2110 NARCISSUS CT VENICE CA 90291 8184226172
Pasithea Therapeutics Corp. (Filer) CIK: 0001841330 (see all company filings)

EIN.: 851591963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40804 | Film No.: 23724393
SIC: 2834 Pharmaceutical Preparations